Author

Catherine Zhang

Observed name: Catherine C. Zhang

Institution: AbbVie (United States)

Observed institutions: AbbVie (United States), AbbVie Biotherapeutics (United States)

OpenAlex ID: A5066787366

A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity

2019 · Shiming Ye, Diane Cohen, et al. · Cancer Immunology Research · 59

ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models

2018 · Yingchun Li, Jonathan A. Hickson, et al. · Molecular Cancer Therapeutics · 46

Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

2024 · Aarif Ahsan, Christine Mantis, et al. · Journal of Clinical Oncology · 1

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

2025 · Aarif Ahsan, Christine Mantis, et al. · Blood

Data from ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models

2023 · Yingchun Li, Jonathan A. Hickson, et al.

Works count: 5

Citation count: 106

H-index: 2

I10-index: 2